文献速递胃肠动力与功能性疾病食管胃疾病与幽门螺杆菌

胃肠道疾病中的回避/限制性摄食障碍

Avoidant/restrictive food intake across the gastrointestinal tract.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-10-09

该研究分析了92名健康志愿者和467名来自七个三级队列的胃肠道疾病患者,评估回避/限制性摄食障碍(ARFID)的筛查阳性率及其与症状严重程度、肠外症状和抑郁评分的关联。结果显示,非食管性疾病(IBS、FD、便秘)的ARFID+患病率高于食管性疾病(反流、癔球症、吞咽困难、贲门失弛缓),且抑郁症状和食物相关腹痛与非食管性疾病的ARFID+独立相关。

要点

  • 非食管性疾病患者ARFID+患病率24%,显著高于食管性疾病的11%。
  • 抑郁症状和食物相关腹痛与非食管性疾病中ARFID+独立相关。
  • 恐惧性食物回避是疼痛相关限制性进食的主要 contributor。

核心结论

  • ARFID症状在非食管性疾病中比食管性疾病更普遍。
  • 在非食管性疾病中,症状严重程度和食物相关腹痛与ARFID+相关,且以恐惧不良后果为特征。

研究设计与样本

  • 研究纳入92名健康志愿者和467名来自七个三级队列的患者:肠易激综合征(IBS,n=88)、功能性消化不良(FD,n=83)、便秘(n=59)、反流(n=107)、癔球症(n=45)、吞咽困难(n=37)和贲门失弛缓(n=48),分为非食管性疾病(IBS、FD、便秘)和食管性疾病(反流、癔球症、吞咽困难、贲门失弛缓)。
  • 评估包括Rome IV标准、肠外症状、抑郁评分(PHQ-12/9)和ARFID筛查;ARFID+定义为NIAS+(至少一个子量表 cutoff:挑食≥10,食欲≥9,恐惧≥10)加上DSM-5损害。
  • 采用多因素logistic回归(三级分层方法)调整症状严重程度、肠外症状和抑郁症状,计算比值比(OR)。

主要发现

  • 与健康志愿者相比,IBS(OR=15.0)、FD(OR=10.6)、便秘(OR=18.2)、反流(OR=5.2)和吞咽困难(OR=7.0)与ARFID+相关,而癔球症或贲门失弛缓不相关。
  • 非食管性疾病与食管性疾病相比,ARFID+患病率更高(24% vs. 11%;OR=2.7,p<0.001),调整后仍显著。
  • 在非食管性疾病中,抑郁症状(OR=1.1)和食物相关腹痛(OR=1.2)与ARFID+独立相关,恐惧性食物回避是疼痛相关限制性进食的主要 contributor(β=0.3,p<0.001)。

关键数值与推荐

  • ARFID+定义为NIAS+(至少一个子量表 cutoff:挑食≥10,食欲≥9,恐惧≥10)加上DSM-5损害。
  • 非食管性疾病与食管性疾病相比,ARFID+患病率24% vs. 11%(OR=2.7,p<0.001)。
  • 在非食管性疾病中,抑郁症状OR=1.1,食物相关腹痛OR=1.2,恐惧性食物回避β=0.3(p<0.001)。

临床怎么用

  • 对非食管性胃肠道疾病患者(如IBS、FD、便秘)应考虑筛查ARFID,尤其是伴有抑郁症状或食物相关腹痛者。
  • ARFID筛查阳性可能以恐惧不良后果为特征,临床干预需关注恐惧性回避机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Avoidant/restrictive food intake disorder (ARFID) is characterized by reduced dietary intake leading to medical and/or psychosocial impairment, independent of body image concerns. We aim to assess ARFID screening and characteristics in patients with gastrointestinal disorders versus healthy volunteers (HV), and its associations with symptom severity, extraintestinal symptoms and depression scores. METHODS: We analyzed 92 HV and 467 patients from seven tertiary cohorts: irritable bowel syndrome (IBS, n=88), functional dyspepsia (FD, n=83), constipation (n=59), reflux (n=107), globus (n=45), dysphagia (n=37), and achalasia (n=48), grouped into non-esophageal (IBS, FD, constipation) and esophageal disorders (reflux, globus, dysphagia and achalasia). Assessments included Rome IV criteria, extraintestinal symptoms and depression scores (PHQ-12/9), and ARFID screening. ARFID+ was defined as NIAS+ (≥1 subscale cutoff: picky eating ≥10, appetite ≥9, fear ≥10) plus DSM-5 impairment. Odds ratios were derived from multiple logistic regression with three-level hierarchical approach adjusted for symptom severity, extra-intestinal, and depression symptoms. RESULTS: Compared to HV, IBS (OR=15.0), FD (OR=10.6), constipation (OR=18.2), reflux (OR=5.2) and dysphagia (OR=7.0) were associated with ARFID+, whereas globus or achalasia were not. A higher prevalence of ARFID+ was observed in non-esophageal versus esophageal disorders (24% vs. 11%; OR=2.7, p<0.001), remaining significant after adjustments. Within non-esophageal disorders, depressive symptoms (OR=1.1) and food-related abdominal pain (OR=1.2) were independently associated with ARFID+, with fear-based food avoidance emerging as primary contributor to pain-related restrictive eating (β=0.3, p<0.001). CONCLUSION: ARFID symptoms are more prevalent across non-esophageal disorders compared to esophageal disorders. Within non-esophageal disorders, symptoms severity and food-related abdominal pain are associated with ARFID+, and mostly characterized by fear of aversive consequences.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Routhiaux K, Van den Houte K, Balsiger L, et al. Avoidant/restrictive food intake across the gastrointestinal tract. Clin Gastroenterol Hepatol. 2026. PMID: 42854770. doi:10.1016/j.cgh.2026.09.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。